RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents
about
Dual kinase-bromodomain inhibitors for rationally designed polypharmacologyBuilding predictive models for mechanism-of-action classification from phenotypic assay data sets.Elucidating mechanisms of toxicity using phenotypic data from primary human cell systems--a chemical biology approach for thrombosis-related side effects.Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participantsRegulation of IL-17A production is distinct from IL-17F in a primary human cell co-culture model of T cell-mediated B cell activationSelective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694.Bruton's TK inhibitors: structural insights and evolution of clinical candidates.Anti-Inflammatory Effects and Joint Protection in Collagen-Induced Arthritis after Treatment with IQ-1S, a Selective c-Jun N-Terminal Kinase Inhibitor.Prolonged and tunable residence time using reversible covalent kinase inhibitors.Discovery of a Potent BTK Inhibitor with a Novel Binding Mode by Using Parallel Selections with a DNA-Encoded Chemical Library.Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function.HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritisTEC and MAPK Kinase Signalling Pathways in T helper (TH) cell Development, TH2 Differentiation and Allergic Asthma.B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies.Ibrutinib and novel BTK inhibitors in clinical development.Quantitative structure-activity relationship study on BTK inhibitors by modified multivariate adaptive regression spline and CoMSIA methods.BTK Signaling in B Cell Differentiation and Autoimmunity.A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers.Old and new therapeutics for Rheumatoid Arthritis: in vivo models and drug development.The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy.Investigational Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.Phenotypic Approaches to Identify Inhibitors of B Cell Activation.Enhanced Bruton's Tyrosine Kinase Activity in Peripheral Blood B Lymphocytes From Patients With Autoimmune Disease.Btk inhibition suppresses agonist-induced human macrophage activation and inflammatory gene expression in RA synovial tissue explants.Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care.HM71224, a selective Bruton's tyrosine kinase inhibitor, attenuates the development of murine lupus.Bruton's tyrosine kinase regulates TLR9 but not TLR7 signaling in human plasmacytoid dendritic cells.Btk Inhibitor RN983 Delivered by Dry Powder Nose-only Aerosol Inhalation Inhibits Bronchoconstriction and Pulmonary Inflammation in the Ovalbumin Allergic Mouse Model of AsthmaDevelopment of a pharmacodynamic assay based on PLCγ2 phosphorylation for quantifying spleen tyrosine kinase (SYK)-Bruton's tyrosine kinase (BTK) signaling.Bruton's Tyrosine Kinase Deficiency Inhibits Autoimmune Arthritis in Mice but Fails to Block Immune Complex-Mediated Inflammatory Arthritis.Genome-Wide Expression Profiles Drive Discovery of Novel Compounds that Reduce Binge Drinking in Mice.Discovery of Novel Bruton's Tyrosine Kinase (BTK) Inhibitors Bearing a N,9-Diphenyl-9H-purin-2-amine Scaffold.Suppression of glomerulonephritis in lupus-prone NZB × NZW mice by RN486, a selective inhibitor of Bruton's tyrosine kinase.Enhanced Expression of Bruton's Tyrosine Kinase in B Cells Drives Systemic Autoimmunity by Disrupting T Cell Homeostasis.European League against rheumatism - selected presentation and poster a highlights June 11th to 13th 2013.Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate.
P2860
Q27681935-8AC8D7F6-A3DF-46ED-AFB1-9DA4863F90E3Q30671097-87251598-A579-4970-8100-61EFF55F830CQ30883298-66510D31-0C02-4423-9021-D06241B02528Q33653945-E5A259DC-580E-48BB-9227-23A7B516B87CQ34626086-19AFAA92-3ADC-4983-B21B-1D0D17922419Q35055978-5D7C4DA2-B910-4BD2-8FD6-616021B4E2ABQ35172875-37A78B3D-5BB4-4744-8F9D-1CE110E45B01Q35181271-57A5C695-40DC-42E8-A472-4F0AE6360E95Q35600218-D41FC69E-E919-4A84-9BDF-099999085DF9Q35756228-42C67AD9-485D-4633-B492-13599D89A44EQ36240548-F9C9A120-1464-451F-AA0F-E25B1B101427Q36548443-C168C20F-2A0A-4849-8A36-0E3BBF66F70CQ36810546-22C3E465-9A92-4C02-B3C6-CD56327A304DQ37219806-E54F58FA-5E28-43BB-8DDF-7AC2C1CFCF33Q38124119-362D73B6-E18C-4364-B0DF-5EDC8B2AE4DBQ38124120-53267913-3D8F-474D-8877-1BDE43B82E56Q38130010-28761BD4-12D3-4260-A93C-82904B1F89CEQ38444266-972B04E2-E6CE-47BE-A38B-547E166EAD20Q38581000-047F1CC3-9E8B-4F4D-A151-F941588DEAC7Q38668551-7453671F-71ED-43DE-90CB-023F8AF2A7E9Q38697262-753E3060-E50B-462B-AE2F-2B9DF4DEB526Q38728631-65FE1620-627E-4C83-A377-F0D138DE37E6Q38826405-9811B78F-C3EC-45D6-957A-A067664E1D42Q38878317-CB2116A7-3392-49E6-A5E2-0EBF5F0DF1F2Q38988830-AA850CED-B677-48B0-9B9D-94F582D2772CQ40186747-8CD7A32B-6E9A-49C8-BDE4-7C15C82E18F4Q41106264-692713E7-E9A2-46C2-B544-265546501DD3Q41670053-2F7A47A2-D213-404F-B687-15C253160AEAQ42234851-77AD6A2E-522D-433A-B3CE-907968DBB2B6Q42329453-3D01A054-EB9E-4FFB-B1A3-E4B49A8117BDQ45982703-AFB703F1-FFBF-4650-B099-396FDDBD58E1Q46333548-F34F57C7-5B17-4BCA-9A72-42F778CA3E2CQ47910117-AA01469E-2B6C-435B-8B8A-0BF794B2164EQ48016248-F666AB8D-9DE7-4A73-9015-24F1268BE00DQ50919840-72EB6BA5-D4FB-4362-B772-EA3C5176AF55Q52671903-E1D48C13-CFAD-451F-80AA-50A02351C81BQ53309302-AC44D769-4154-435C-8DDD-095E57513700Q55310713-E7BD4C58-4CE3-4321-A228-63CEDF5ECB0F
P2860
RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents
description
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2012
@ast
im April 2012 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2012/04/01)
@sk
vědecký článek publikovaný v roce 2012
@cs
wetenschappelijk artikel (gepubliceerd op 2012/04/01)
@nl
наукова стаття, опублікована у квітні 2012
@uk
مقالة علمية (نشرت في أبريل 2012)
@ar
name
RN486, a selective Bruton's ty ...... onses and arthritis in rodents
@ast
RN486, a selective Bruton's ty ...... onses and arthritis in rodents
@en
RN486, a selective Bruton's ty ...... onses and arthritis in rodents
@nl
type
label
RN486, a selective Bruton's ty ...... onses and arthritis in rodents
@ast
RN486, a selective Bruton's ty ...... onses and arthritis in rodents
@en
RN486, a selective Bruton's ty ...... onses and arthritis in rodents
@nl
prefLabel
RN486, a selective Bruton's ty ...... onses and arthritis in rodents
@ast
RN486, a selective Bruton's ty ...... onses and arthritis in rodents
@en
RN486, a selective Bruton's ty ...... onses and arthritis in rodents
@nl
P2093
P356
P1476
RN486, a selective Bruton's ty ...... onses and arthritis in rodents
@en
P2093
Achal Pashine
Alison O'Mahony
Anita Levin
Cheng Liao
Dinesh Srinivasan
Dong-Qing Hu
Jay S Fine
John Woods
Jonathan Hsu
P304
P356
10.1124/JPET.111.187740
P407
P577
2012-01-06T00:00:00Z